title: The effect of pubertal delay on adult height in men with isolated hypogonadotropic hypogonadism.
abstract: To determine whether delay of puberty alters adult height, we retrospectively evaluated the adult height of 41 patients who met rigorous criteria for the diagnosis of isolated hypogonadotropic hypogonadism. The adult height of these patients was compared with the mean height of normal American men at age 18 in the 1979 National Center for Health Statistics survey and with the mean adult height of 50 male normal volunteers who had been studied on the same wards as the patients with hypogonadotropic hypogonadism. The mean adult height of the men with isolated hypogonadotropic hypogonadism was 179.7 cm, which exceeded the height of the 50 control subjects and the normal American men (both 176.8 cm) by 2.9 cm (P less than 0.05 and P less than 0.006, respectively). The mean age at treatment to induce puberty was 20.0 yr, which corresponded to a mean delay in the onset of puberty of more than 8 yr relative to normal males. The final height of the men with hypogonadotropic hypogonadism correlated significantly with the duration of pubertal delay (r = 0.32, P = 0.04). Most of the enhanced mean adult height of the patients with isolated hypogonadotropic hypogonadism was attributable to those patients in whom treatment to induce puberty had been delayed to age 18 or greater. The mean adult height of these patients was 182.4 cm, or 5.6 cm greater than the mean height of the 50 controls or of normal American men (P less than 0.001). The mean adult height of patients whose treatment began between 10 and 17 yr of age was 175.0 cm, which did not differ significantly from that of normal men. We conclude that prolonged delay of puberty (6 or more yr) in men with isolated hypogonadotropic hypogonadism is associated with a modest increase (approximately 5 cm) of adult height.
authors.affiliation: Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: M M
authors.initials: MM
authors.lastname: Uriarte
authors.forename: J
authors.initials: J
authors.lastname: Baron
authors.forename: H B
authors.initials: HB
authors.lastname: Garcia
authors.forename: K M
authors.initials: KM
authors.lastname: Barnes
authors.forename: D L
authors.initials: DL
authors.lastname: Loriaux
authors.forename: G B
authors.initials: GB
authors.lastname: Cutler
mesh_terms: D000293:Adolescent; D000328:Adult; D001827:Body Height; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000503:physiopathology*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008596:Menotropins / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D011628:Puberty, Delayed / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D012016:Reference Values; D012189:Retrospective Studies; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use*
chemical_list: D006063:Chorionic Gonadotropin; D013739:Testosterone; D008596:Menotropins; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone